Every one of those 1 sits in a single category, clinical-trial. Stargardt disease is most often covered alongside Belite Bio, which appears in 1 of these 1 story. Stargardt disease appears in 1 tracked Biotech story from March 11, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Stargardt disease
Every one of those 1 sits in a single category, clinical-trial. Stargardt disease is most often covered alongside Belite Bio, which appears in 1 of these 1 story. Stargardt disease appears in 1 tracked Biotech story from March 11, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Stargardt disease. Shared-story counts are live from our verified record — not editorial picks.
Belite Bio (BLTE) has reported positive Phase 3 DRAGON trial results for its lead candidate, Tinlarebant, demonstrating a 36% reduction in lesion growth for Stargardt disease. The oral therapy is now positioned for a Q2 2026 NDA submission as the company prepares for a $200M-$250M commercial launch.